Nicolas Dickgreber

Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease

Petra Hoffknecht, Amanda Tufman, Thomas Wehler et al. · Journal of Thoracic Oncology · 2014 · 250 citations · Full text

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials

James Chih‐Hsin Yang, Lecia V. Sequist, Caicun Zhou et al. · Annals of Oncology · 2016 · 182 citations

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

Martin Schüler, James Chih‐Hsin Yang, K. Park et al. · Annals of Oncology · 2015 · 131 citations · Full text

GILT—A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer

Michael Flentje, Rudolf M. Huber, Walburga Engel-Riedel et al. · Strahlentherapie und Onkologie · 2016 · 73 citations

Radiation Medicine, Radiation Therapy, Medicine +10

Preclinical analyses and phase I evaluation of LY2603618 administered in combination with Pemetrexed and cisplatin in patients with advanced cancer

Emiliano Calvo, Victor J. Chen, Mark S. Marshall et al. · Investigational New Drugs · 2014 · 57 citations

Advanced Cancer, Medicine, Pharmacology +6